A BCMA Setback For Bristol And Bluebird With FDA Refuse-To-File Letter

The US FDA took issue with the CMC portion of the BLA for the BCMA-targeted therapy idecabtagene vicleucel for multiple myeloma. An approval is tied to a $9 CVR for Celgene shareholders.